FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. (FBLG) filed an 8-K reporting results of its June 22, 2026 Annual Meeting. Stockholders approved the FibroBiologics 2026 Equity and Incentive Compensation Plan (the “2026 Plan”), elected Pete O’Heeron as a Class III director (term to 2029), and ratified WithumSmith+Brown, PC as the company’s independent auditor for 2026. The company reported 4,174,791 votes represented at the meeting out of 6,833,915 shares entitled to vote as of the April 24, 2026 record date.

Key Details

• 2026 Plan approved and effective June 22, 2026; 2,061,968 shares available for awards initially (2,000,000 new shares + 61,968 remaining from predecessor plan).
• Plan includes an “evergreen” increase on the first day of each fiscal year 2027–2036 equal to the lesser of 4% of outstanding common shares or a smaller Board-determined amount.
• Aggregate limit of 2,000,000 shares that may be issued upon exercise of incentive stock options; non-employee director compensation capped at $800,000 per calendar year (per plan rules).
• Director election vote: Pete O’Heeron elected with 2,795,804 For, 119,185 Against, 27,511 Abstain; broker non-votes: 1,232,291. Auditor ratification vote: 4,112,372 For, 43,143 Against, 19,276 Abstain.
• Shareholder approval also covered Nasdaq-related approval for issuance of up to 2,272,728 shares issuable upon exercise of certain March 31, 2026 warrants and up to 159,091 shares tied to a November 10, 2025 engagement letter (as amended).

Why It Matters
Approval of the 2026 Plan gives the company a multi-year mechanism to grant stock- and cash-based awards to employees, officers, consultants and directors, which management uses to attract and retain talent and incentivize performance. The new share reserve and annual “evergreen” increases create potential future dilution for existing shareholders (the filing specifies share counts and annual caps). The director election and auditor ratification are routine governance matters that confirm board composition and the independent accounting firm for 2026. Investors should review the full plan text (filed as Exhibit 10.1) for details on award types, share-counting rules and adjustment provisions.